The dermal fillers market would grow at a CAGR of 8.01% over the predicted time frame. The market is expected to increase in value from US$ 7.24 Bn in 2022 to US$ 13.4Bn in 2030.
The on dermal fillers Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2100
Report Scope of the Dermal Fillers Market
| Report Coverage | Details |
| Market Size in 2022 | USD 7.24 Billion |
| Market Size by 2030 | USD 13.4 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 8.01% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Material, Product, Drug Type, Application, End User, and Geography |
A recent report provides crucial insights along with application based and forecast information in the Global Dermal fillers Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Dermal fillers market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Dermal fillers market are included as given below:
Dermal fillers Market Key Players
- AbbVie, Inc.
- HUADONG MEDICINE CO., LTD
- BIOPLUS CO., LTD.
- TEOXANE LABORATORIES
- BIOHA LABORATORIES
- Prollenium Medical Technologies
- Galderma
- Merz Pharma
- Suneva Medical
- BIOXIS pharmaceuticals
Market Segments
By Material
- Hyaluronic acid
- Calcium hydroxyl apatite
- Poly-L-lactic Acid
- PMMA (Poly(methyl methacrylate))
- Fat Fillers
- Others
By Product
- Non-biodegradable
- Biodegradable
- Temporary biodegradable
- Semi-Permanent biodegradable
By Drug Type
- Branded
- Generic
By Application
- Wrinkle Correction Treatment
- Scar treatment
- Lip enhancement
- Restoration of volume
- Others
By End User
- Specialty and Dermatology Clinics
- Clinics and Hospitals
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global dermal fillers market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the dermal fillers market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dermal Fillers Market
5.1. COVID-19 Landscape: Dermal Fillers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dermal Fillers Market, By Material
8.1. Dermal Fillers Market, by Material, 2022-2030
8.1.1. Hyaluronic acid
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Calcium hydroxyl apatite
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Poly-L-lactic Acid
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. PMMA (Poly(methyl methacrylate))
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Fat Fillers
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Dermal Fillers Market, By Product
9.1. Dermal Fillers Market, by Product, 2022-2030
9.1.1. Non-biodegradable
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Biodegradable
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Dermal Fillers Market, By Drug Type
10.1. Dermal Fillers Market, by Drug Type, 2022-2030
10.1.1. Branded
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Generic
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Dermal Fillers Market, By Application
11.1. Dermal Fillers Market, by Application, 2022-2030
11.1.1. Wrinkle Correction Treatment
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Scar treatment
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Lip enhancement
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Restoration of volume
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Dermal Fillers Market, By End User
12.1. Dermal Fillers Market, by End User, 2022-2030
12.1.1. Specialty and Dermatology Clinics
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Clinics and Hospitals
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. OSAT
Chapter 13. Global Dermal Fillers Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Material (2017-2030)
13.1.2. Market Revenue and Forecast, by Product (2017-2030)
13.1.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.1.4. Market Revenue and Forecast, by Application (2017-2030)
13.1.5. Market Revenue and Forecast, by End User (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Material (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Product (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Application (2017-2030)
13.1.6.5. Market Revenue and Forecast, by End User (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Material (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Product (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Application (2017-2030)
13.1.7.5. Market Revenue and Forecast, by End User (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Material (2017-2030)
13.2.2. Market Revenue and Forecast, by Product (2017-2030)
13.2.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.2.4. Market Revenue and Forecast, by Application (2017-2030)
13.2.5. Market Revenue and Forecast, by End User (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Material (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Product (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.2.7. Market Revenue and Forecast, by Application (2017-2030)
13.2.8. Market Revenue and Forecast, by End User (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Material (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Product (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.2.10. Market Revenue and Forecast, by Application (2017-2030)
13.2.11. Market Revenue and Forecast, by End User (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Material (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Product (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Application (2017-2030)
13.2.13. Market Revenue and Forecast, by End User (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Material (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Product (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Application (2017-2030)
13.2.15. Market Revenue and Forecast, by End User (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Material (2017-2030)
13.3.2. Market Revenue and Forecast, by Product (2017-2030)
13.3.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.3.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.5. Market Revenue and Forecast, by End User (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Material (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Product (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.7. Market Revenue and Forecast, by End User (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Material (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Product (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.9. Market Revenue and Forecast, by End User (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Material (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Product (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.10.5. Market Revenue and Forecast, by End User (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Material (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Product (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Application (2017-2030)
13.3.11.5. Market Revenue and Forecast, by End User (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Material (2017-2030)
13.4.2. Market Revenue and Forecast, by Product (2017-2030)
13.4.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.4.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.5. Market Revenue and Forecast, by End User (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Material (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Product (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.7. Market Revenue and Forecast, by End User (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Material (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Product (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.9. Market Revenue and Forecast, by End User (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Material (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Product (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.10.5. Market Revenue and Forecast, by End User (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Material (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Product (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Application (2017-2030)
13.4.11.5. Market Revenue and Forecast, by End User (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Material (2017-2030)
13.5.2. Market Revenue and Forecast, by Product (2017-2030)
13.5.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.5.4. Market Revenue and Forecast, by Application (2017-2030)
13.5.5. Market Revenue and Forecast, by End User (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Material (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Product (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Application (2017-2030)
13.5.7. Market Revenue and Forecast, by End User (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Material (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Product (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Drug Type (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Application (2017-2030)
13.5.8.5. Market Revenue and Forecast, by End User (2017-2030)
Chapter 14. Company Profiles
14.1. AbbVie, Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. HUADONG MEDICINE CO., LTD
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. BIOPLUS CO., LTD.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. TEOXANE LABORATORIES
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. BIOHA LABORATORIES
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Prollenium Medical Technologies
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Galderma
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Merz Pharma
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Suneva Medical
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. BIOXIS pharmaceuticals
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments